Pasithea Therapeutics Cor... (KTTA)
2.46
-0.03 (-1.20%)
At close: Jan 15, 2025, 12:44 PM
undefined% (undefined)
| Bid | 2.45 |
| Market Cap | 3.12M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -14.79 |
| PE Ratio (ttm) | -0.17 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.51 |
| Volume | 23,662 |
| Avg. Volume (20D) | 43,793 |
| Open | 2.52 |
| Previous Close | 2.49 |
| Day's Range | 2.45 - 2.61 |
| 52-Week Range | 2.20 - 9.25 |
| Beta | undefined |
About KTTA
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida....
Industry Biotechnology
Sector Healthcare
IPO Date Sep 15, 2021
Employees 8
Stock Exchange NASDAQ
Ticker Symbol KTTA
Website https://www.pasithea.com
Analyst Forecast
According to 1 analyst ratings, the average rating for KTTA stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
3 months ago ·
Source
+51.95%
Pasithea Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
